Compare ESRT & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESRT | CSTL |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 913.4M | 806.3M |
| IPO Year | 2012 | 2019 |
| Metric | ESRT | CSTL |
|---|---|---|
| Price | $5.55 | $25.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $6.35 | ★ $45.50 |
| AVG Volume (30 Days) | ★ 1.3M | 253.5K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $768,270,000.00 | $344,229,000.00 |
| Revenue This Year | $4.26 | $2.42 |
| Revenue Next Year | $1.52 | $12.69 |
| P/E Ratio | $22.34 | ★ N/A |
| Revenue Growth | 0.05 | ★ 3.66 |
| 52 Week Low | $4.87 | $14.59 |
| 52 Week High | $8.76 | $44.28 |
| Indicator | ESRT | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 51.63 | 51.21 |
| Support Level | $4.87 | $24.89 |
| Resistance Level | $6.70 | $26.20 |
| Average True Range (ATR) | 0.17 | 0.95 |
| MACD | 0.02 | 0.21 |
| Stochastic Oscillator | 49.02 | 79.72 |
Empire State Realty Trust Inc is a real estate investment trust (REIT) that owns and operates office, retail, and multifamily properties located in New York City, prominently in Manhattan. Its portfolio includes office and retail space as well as residential units. The company's objective is to maximize cash flow and total returns to its shareholders and to increase the value of the properties. Its reportable segments consist of a real estate segment and an Observatory segment. The majority of revenue is derived from the Real Estate segment, which includes all activities related to the ownership, management, operation, acquisition, redevelopment, repositioning and disposition of its traditional real estate assets.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.